Kazia’s Therapeutics Chief Executive Officer Dr James Garner was featured in a recent article in The Australian Financial Review on the new breed of biotechnology companies.
In the interview, Dr Garner spoke about the importance of networks and collaborations in the biotech industry and how Kazia focuses on structuring and managing the approvals and trial stages of drug development.
The article also talks about the five ongoing trials with Kazia’s lead candidate, GDC-0084 and our recent announcement that leading US cancer treatment centre, Memorial Sloan Kettering (MSK), will use GDC-0084 in a phase I clinical trial for cancer that has spread to the brain (brain metastases).
Read the article here.
Interview with Proactive Investors
Also recently, Dr Garner also discussed the ongoing clinical program with GDC-0084 and the completion of recruitment for Part B of the Cantrixil trial in an interview with Proactive Investors.
In the interview, Dr Garner also discusses:
• Kazia’s strategy with GDC-0084
• How equity market volatility impacts Kazia
• The upcoming milestones and value catalysts for the company
Watch the video interview here.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.